DE60334711D1 - Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren - Google Patents
Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumorenInfo
- Publication number
- DE60334711D1 DE60334711D1 DE60334711T DE60334711T DE60334711D1 DE 60334711 D1 DE60334711 D1 DE 60334711D1 DE 60334711 T DE60334711 T DE 60334711T DE 60334711 T DE60334711 T DE 60334711T DE 60334711 D1 DE60334711 D1 DE 60334711D1
- Authority
- DE
- Germany
- Prior art keywords
- cholesterol
- treatment
- associated tumor
- ezetimibe
- ezetimib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 title abstract 6
- 229960000815 ezetimibe Drugs 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 10
- 235000012000 cholesterol Nutrition 0.000 abstract 5
- 230000002265 prevention Effects 0.000 abstract 3
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 abstract 2
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 abstract 2
- 229930182480 glucuronide Natural products 0.000 abstract 2
- -1 phenolic glucuronide Chemical class 0.000 abstract 2
- DPZUDTYEZMUJDW-GMUMFXLYSA-N (1r)-7-(4-chlorophenyl)-2-(4-fluorophenyl)-7-hydroxy-1-(4-hydroxyphenyl)-2-azaspiro[3.5]nonan-3-one Chemical compound C1=CC(O)=CC=C1[C@@H]1C2(CCC(O)(CC2)C=2C=CC(Cl)=CC=2)C(=O)N1C1=CC=C(F)C=C1 DPZUDTYEZMUJDW-GMUMFXLYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229940127084 other anti-cancer agent Drugs 0.000 abstract 1
- IMNTVVOUWFPRSB-JWQCQUIFSA-N sch-48461 Chemical compound C1=CC(OC)=CC=C1[C@H]1N(C=2C=CC(OC)=CC=2)C(=O)[C@@H]1CCCC1=CC=CC=C1 IMNTVVOUWFPRSB-JWQCQUIFSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39969002P | 2002-07-30 | 2002-07-30 | |
| PCT/US2003/023764 WO2004010948A2 (en) | 2002-07-30 | 2003-07-30 | Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors |
| US10/630,578 US6933292B2 (en) | 2002-07-30 | 2003-07-30 | Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60334711D1 true DE60334711D1 (de) | 2010-12-09 |
Family
ID=32511171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60334711T Expired - Lifetime DE60334711D1 (de) | 2002-07-30 | 2003-07-30 | Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US6933292B2 (de) |
| EP (1) | EP1545479B1 (de) |
| JP (1) | JP2006501205A (de) |
| CN (1) | CN1678296A (de) |
| AT (1) | ATE485818T1 (de) |
| AU (1) | AU2003254261B2 (de) |
| CA (1) | CA2493614C (de) |
| DE (1) | DE60334711D1 (de) |
| NZ (1) | NZ538498A (de) |
| WO (1) | WO2004010948A2 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2009027B1 (de) | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Monoklonaler Antikörper gegen CD40 |
| GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| WO2004010948A2 (en) * | 2002-07-30 | 2004-02-05 | Karykion Inc. | Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors |
| KR20060135615A (ko) * | 2003-09-26 | 2006-12-29 | 포비스 메디-테크 인코포레이티드 | 다중-약물 내성 유전자의 발현을 억제하는 방법 및 그유전자의 발현으로부터 유발된 단백질의 생성을 억제하고그로써 암 치료를 위한 화학요법제의 효능을 증강시키는방법 |
| WO2005061452A1 (en) | 2003-12-23 | 2005-07-07 | Astrazeneca Ab | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
| US8361999B2 (en) | 2005-04-04 | 2013-01-29 | Pontificia Universidad Catolica De Chile | Methods of treating cholesterol gallstone disease with ezetimibe |
| SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| TW200811098A (en) | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| US20070275052A1 (en) * | 2006-05-24 | 2007-11-29 | Glenmark Pharmaceuticals Limited | Pharmaceutical compositions containing sterol inhibitors |
| US20090208448A1 (en) * | 2008-02-15 | 2009-08-20 | Solomon Keith R | Inhibition of angiogenesis |
| EP2337570A4 (de) * | 2008-09-02 | 2012-03-28 | Univ Illinois | Zusammensetzungen und verfahren zur hemmung des eintritts eines hepatischen virus |
| US9034863B2 (en) | 2008-09-02 | 2015-05-19 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for inhibiting entry of a hepatic virus |
| WO2015065505A1 (en) * | 2013-10-29 | 2015-05-07 | Duke University | Use of cyp27a1 inhibitors, statin, or lxr antagonists alone or in combination with conventional therapy for the treatment of breast cancer |
| US20220387383A1 (en) * | 2019-11-12 | 2022-12-08 | University Of South Africa | Ezetimibe and curcumin for use in cancer treatment |
| WO2022087437A1 (en) * | 2020-10-22 | 2022-04-28 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Methods of treatment |
| CN115364094A (zh) * | 2021-05-19 | 2022-11-22 | 南京大学 | 伊折麦布在制备抗肿瘤药物中的应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE637389A (de) * | 1962-09-13 | |||
| US3622437A (en) * | 1969-05-09 | 1971-11-23 | Gen Dynamics Corp | Composite buoyancy material |
| EP0002097B1 (de) * | 1977-08-22 | 1981-08-05 | Imperial Chemical Industries Plc | Triphenylalken-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten |
| DE3046719C2 (de) * | 1980-12-11 | 1983-02-17 | Klinge Pharma GmbH, 8000 München | 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US4719207A (en) * | 1984-06-25 | 1988-01-12 | Yamanouchi Pharmaceutical Co., Ltd. | CNS active substituted azetidinone compounds |
| US4639420A (en) * | 1984-11-21 | 1987-01-27 | Schaffner Carl P | Method for the immunoanalysis of cholesterol epoxides |
| DE3762617D1 (de) * | 1986-09-11 | 1990-06-13 | Nat Res Dev | Tamoxifenderivate. |
| JP3350048B2 (ja) * | 1989-07-07 | 2002-11-25 | アンドルシェルシュ・インコーポレイテッド | アンドロゲン関連疾患の治療方法 |
| SK7994A3 (en) * | 1991-07-23 | 1994-07-06 | Schering Corp | Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes of their preparation |
| AU680818B2 (en) * | 1992-05-21 | 1997-08-14 | Endorecherche Inc. | Improved antiandrogens |
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| LT3595B (en) * | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5972383A (en) * | 1994-03-02 | 1999-10-26 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
| US5613460A (en) * | 1994-08-31 | 1997-03-25 | Newport News Shipbuilding And Dry Dock Company | Submersible vessel external load mounting system |
| US6395770B1 (en) * | 1995-10-26 | 2002-05-28 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
| US5919815A (en) * | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
| JPH10179086A (ja) * | 1996-11-05 | 1998-07-07 | Riken Vitamin Co Ltd | 植物ステロールを含有する油溶化液及び飲食物並びにその製造方法 |
| US6245352B1 (en) * | 1999-04-27 | 2001-06-12 | Eli Lilly And Company | Pharmaceutical formulation |
| US6380405B1 (en) * | 1999-09-13 | 2002-04-30 | Nobex Corporation | Taxane prodrugs |
| JP2003522790A (ja) * | 2000-02-17 | 2003-07-29 | メルク エンド カムパニー インコーポレーテッド | Ｃｏｘ−２選択的阻害薬を用いた前立腺癌の治療または予防 |
| US20020013334A1 (en) * | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| AU2001288724A1 (en) * | 2000-09-06 | 2002-03-22 | Merck & Co., Inc. | Dihydroxy open-acid salt of simvastatin |
| WO2002026729A2 (en) | 2000-09-27 | 2002-04-04 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| US6534540B2 (en) * | 2000-10-06 | 2003-03-18 | George Kindness | Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor |
| IL156552A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| EP1354888B1 (de) * | 2000-12-28 | 2009-05-20 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln |
| EP1859796A3 (de) | 2001-09-21 | 2008-07-02 | Schering Corporation | Behandlung von xanthom mit azetidinon-derivaten als hemmer der sterol absorption |
| WO2004010948A2 (en) * | 2002-07-30 | 2004-02-05 | Karykion Inc. | Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors |
| US20040145092A1 (en) * | 2003-01-24 | 2004-07-29 | Mccollum Robert P. | Method of making a composite molded article |
| US7263028B2 (en) * | 2003-10-09 | 2007-08-28 | United States Of America As Represented By The Secretary Of The Navy | Composite acoustic attenuation materials |
-
2003
- 2003-07-30 WO PCT/US2003/023764 patent/WO2004010948A2/en active Application Filing
- 2003-07-30 EP EP03772067A patent/EP1545479B1/de not_active Expired - Lifetime
- 2003-07-30 AT AT03772067T patent/ATE485818T1/de not_active IP Right Cessation
- 2003-07-30 CN CNA038205904A patent/CN1678296A/zh active Pending
- 2003-07-30 AU AU2003254261A patent/AU2003254261B2/en not_active Ceased
- 2003-07-30 CA CA2493614A patent/CA2493614C/en not_active Expired - Lifetime
- 2003-07-30 US US10/630,578 patent/US6933292B2/en not_active Expired - Lifetime
- 2003-07-30 JP JP2004525042A patent/JP2006501205A/ja active Pending
- 2003-07-30 DE DE60334711T patent/DE60334711D1/de not_active Expired - Lifetime
- 2003-07-30 NZ NZ538498A patent/NZ538498A/en not_active IP Right Cessation
-
2005
- 2005-05-12 US US11/128,140 patent/US7098198B2/en not_active Expired - Fee Related
-
2006
- 2006-07-13 US US11/485,773 patent/US7449453B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1545479A2 (de) | 2005-06-29 |
| WO2004010948A3 (en) | 2004-07-01 |
| US6933292B2 (en) | 2005-08-23 |
| US20070037755A1 (en) | 2007-02-15 |
| EP1545479A4 (de) | 2007-10-24 |
| CA2493614A1 (en) | 2004-02-05 |
| US20040116358A1 (en) | 2004-06-17 |
| NZ538498A (en) | 2009-02-28 |
| WO2004010948A2 (en) | 2004-02-05 |
| ATE485818T1 (de) | 2010-11-15 |
| US20050209167A1 (en) | 2005-09-22 |
| JP2006501205A (ja) | 2006-01-12 |
| EP1545479B1 (de) | 2010-10-27 |
| US7098198B2 (en) | 2006-08-29 |
| US7449453B2 (en) | 2008-11-11 |
| CN1678296A (zh) | 2005-10-05 |
| AU2003254261A1 (en) | 2004-02-16 |
| AU2003254261B2 (en) | 2008-04-17 |
| CA2493614C (en) | 2011-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60334711D1 (de) | Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren | |
| DE60031268D1 (de) | Verfahren und zusammansetzung zur behandlung von krebs | |
| IS8395A (is) | Fjölvasýklískar karboxýlsýrur og asýlsúlfónamíð sem hindrar á lifrabólgu C eftirmyndun | |
| IL162214A (en) | Pyridine derivatives and pharmaceutical compositions containing the same | |
| WO2001072721A3 (en) | Synergistic methods and compositions for treating cancer | |
| DE69713526D1 (de) | Lösliche prodrugs von paclitaxel | |
| DE602004030222D1 (de) | 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen | |
| RS49756B (sr) | Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksikacija | |
| ATE267798T1 (de) | Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung | |
| AR035533A1 (es) | Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la | |
| DE69822659D1 (de) | Formulierungen und verfahren zur verminderung der toxizität von anti-neoplastischen mitteln | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| RU94029662A (ru) | Фосфонооксиметиловые эфиры производных таксана, фармацевтическая композиция, способы лечения | |
| HUP0303923A2 (hu) | Szterin abszorpció inhibitor(ok)kombinációi kardiovaszkuláris szerekkel vaszkuláris kondíciók kezelésére és a kombinációt tartalmazó készítmények | |
| EP1819227A4 (de) | Pharmazeutische formulierungen von decitabin | |
| DE69837324D1 (de) | Behandlung der multiplen sklerose durch einnahme von copolymer-1 | |
| BR0015698A (pt) | Composições e métodos para tratamento de doenças alérgicas | |
| ATE260282T1 (de) | Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen | |
| ATE415965T1 (de) | Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung | |
| ATE393624T1 (de) | Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs | |
| CA2301590A1 (en) | 2-aminopyridines as inhibitors of cyclooxygenase-2 | |
| DE50109320D1 (de) | Verwendung von 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz | |
| AR022130A1 (es) | Nuevos derivados de arilalcanoilo, los procesos para su preparacion, uso y las composiciones farmaceuticas que los contienen | |
| ATE321553T1 (de) | Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie | |
| DE69938939D1 (de) | Pharmazeutische Zusammensetzung enthaltend Beclomethason-Dipropional zur Behandlung entzündlicher Darmerkrankungen |